JPH0584259A - 耳への薬理学的活性剤の拡張された送出装置及び方法 - Google Patents
耳への薬理学的活性剤の拡張された送出装置及び方法Info
- Publication number
- JPH0584259A JPH0584259A JP3620291A JP3620291A JPH0584259A JP H0584259 A JPH0584259 A JP H0584259A JP 3620291 A JP3620291 A JP 3620291A JP 3620291 A JP3620291 A JP 3620291A JP H0584259 A JPH0584259 A JP H0584259A
- Authority
- JP
- Japan
- Prior art keywords
- middle ear
- ear
- shape
- active agent
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 title abstract 2
- 230000000144 pharmacologic effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 17
- 210000000959 ear middle Anatomy 0.000 claims abstract description 134
- 238000003780 insertion Methods 0.000 claims abstract description 23
- 230000037431 insertion Effects 0.000 claims abstract description 23
- 206010033078 Otitis media Diseases 0.000 claims abstract description 15
- 208000022760 infectious otitis media Diseases 0.000 claims abstract description 8
- 230000000717 retained effect Effects 0.000 claims abstract description 8
- 239000013543 active substance Substances 0.000 claims description 38
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 abstract description 28
- 239000000463 material Substances 0.000 abstract description 20
- 210000003027 ear inner Anatomy 0.000 abstract description 8
- 229920002689 polyvinyl acetate Polymers 0.000 abstract description 2
- 239000011118 polyvinyl acetate Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 26
- 229960000723 ampicillin Drugs 0.000 description 22
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 20
- 239000003242 anti bacterial agent Substances 0.000 description 19
- 210000000416 exudates and transudate Anatomy 0.000 description 19
- 229940088710 antibiotic agent Drugs 0.000 description 15
- 239000000499 gel Substances 0.000 description 13
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 12
- 239000012530 fluid Substances 0.000 description 11
- 229920000747 poly(lactic acid) Polymers 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 241000700112 Chinchilla Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 210000002388 eustachian tube Anatomy 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003454 tympanic membrane Anatomy 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000005141 Otitis Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000613 ear canal Anatomy 0.000 description 3
- 208000019258 ear infection Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 229940047652 ear drops Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000017119 Labyrinth disease Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003431 anti-prostaglandin Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009730 filament winding Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 208000022949 middle ear disease Diseases 0.000 description 1
- 206010033103 otosclerosis Diseases 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001050 stape Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48865090A | 1990-03-05 | 1990-03-05 | |
| US488650 | 1990-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0584259A true JPH0584259A (ja) | 1993-04-06 |
Family
ID=23940561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3620291A Pending JPH0584259A (ja) | 1990-03-05 | 1991-03-01 | 耳への薬理学的活性剤の拡張された送出装置及び方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0447719B1 (de) |
| JP (1) | JPH0584259A (de) |
| DE (1) | DE69004415D1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009508969A (ja) * | 2005-09-22 | 2009-03-05 | メディバス エルエルシー | 固体ポリマー送達組成物およびその使用法 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2691360B1 (fr) * | 1992-05-20 | 1995-06-30 | 3P Agence Conseil | Compositions pharmaceutiques destinees en particulier au traitement des poches parondontales et procede de fabrication. |
| ATE313341T1 (de) * | 2000-01-11 | 2006-01-15 | Intralytix Inc | Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen |
| US6703040B2 (en) | 2000-01-11 | 2004-03-09 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
| US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| CN1655771A (zh) * | 2002-05-24 | 2005-08-17 | 艾克发照像有限责任公司 | 含有活性化合物且至少部分可降解的膜及其制备方法 |
| CA2623198C (en) | 2005-09-22 | 2014-08-05 | Medivas, Llc | Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use |
| DE102010043332B3 (de) * | 2010-11-03 | 2011-10-20 | Universität Rostock | Tubenstent zur Belüftung der Tuben des Mittelohres eines Patienten |
| ES2992024T3 (es) | 2011-06-23 | 2024-12-05 | Dsm Ip Assets Bv | Nuevos copolímeros de poliesteramida biodegradables para la administración de fármacos |
| US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
| WO2014004512A1 (en) | 2012-06-25 | 2014-01-03 | Surmodics, Inc. | Bioerodable poly(etheresteramides) and medical article uses |
| US9510976B2 (en) * | 2014-04-29 | 2016-12-06 | Abbott Cardiovascular Systems Inc. | Devices and methods for treatment of the Eustachian tube and sinus cavity |
| US10434071B2 (en) | 2014-12-18 | 2019-10-08 | Dsm Ip Assets, B.V. | Drug delivery system for delivery of acid sensitivity drugs |
| US20180264241A1 (en) * | 2017-03-20 | 2018-09-20 | Donald PLANCE | Devices and methods for delivering subtances for improved wellbeing |
| KR102084146B1 (ko) * | 2019-09-03 | 2020-03-04 | (주)제이앤킴 | 이관 기능부전 치료를 위한 이관 내 삽입 스텐트 |
| CA3160955A1 (en) | 2019-11-12 | 2021-05-20 | Dsm Ip Assets B.V. | Polyesteramide copolymers possessing high glass transition temperatures |
| CN115192249B (zh) * | 2022-06-24 | 2024-04-30 | 柏为（武汉）医疗科技股份有限公司 | 一种可修剪外耳道支架 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| US4758435A (en) * | 1986-08-11 | 1988-07-19 | American Cyanamid Company | Estradiol implant composition and method for preparation |
| DE3734223A1 (de) * | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | Implantierbares, biologisch abbaubares wirkstofffreigabesystem |
| FI83729C (fi) * | 1987-11-26 | 1991-08-26 | Biocon Oy | Kirurgisk implantat. |
-
1990
- 1990-12-18 EP EP90313800A patent/EP0447719B1/de not_active Expired - Lifetime
- 1990-12-18 DE DE90313800T patent/DE69004415D1/de not_active Expired - Lifetime
-
1991
- 1991-03-01 JP JP3620291A patent/JPH0584259A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009508969A (ja) * | 2005-09-22 | 2009-03-05 | メディバス エルエルシー | 固体ポリマー送達組成物およびその使用法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69004415D1 (de) | 1993-12-09 |
| EP0447719A1 (de) | 1991-09-25 |
| EP0447719B1 (de) | 1993-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5350580A (en) | Device and method for extended delivery of pharmacologically active agents to the ear | |
| EP0447719B1 (de) | Vorrichtung zur verzögerten Abgabe von pharmakologisch aktiven Verbindungen ins Ohr | |
| Caló et al. | Biomedical applications of hydrogels: A review of patents and commercial products | |
| US10357595B2 (en) | Agent for regenerating tympanic membrane or external auditory canal | |
| US8197552B2 (en) | Eustachian tube device and method | |
| CA2620374C (en) | Pharmaceutical compositions for the treatment of inner ear disorders | |
| JP6397491B2 (ja) | キトサンステント材ペースト | |
| EP1438942A1 (de) | Medikamentenabgabevorrichtung für das Mittelohr und Nase | |
| EP0782448A4 (de) | Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen | |
| WO2000033775A1 (en) | Controlled release system for delivering therapeutic agents into the inner ear | |
| JP6297180B2 (ja) | シプロフロキサシン組成物の滅菌 | |
| Igarashi et al. | Cochlear ototoxicity of chlorhexidine gluconate in cats | |
| KR20160047490A (ko) | 소아 귀 질환의 치료 | |
| Thakur et al. | Development and optimization of controlled release bioerodable anti infective ophthalmic insert | |
| JP7294641B2 (ja) | 顔面神経麻痺治療用組成物 | |
| Goycoolea et al. | Sustained release of antimicrobials in the middle ear using a biodegradable support | |
| KR101865671B1 (ko) | 약물을 포함하는 기관 재생 유도관 및 이의 제조방법 | |
| CN118697697A (zh) | 一种脂质体封装的长效罗哌卡因缓释系统 | |
| JP2022043368A (ja) | 感音難聴治療用組成物 |